Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis

The primary objective was to evaluate ICU mortality at 28 days in patients with severe hypoxemic respiratory failure due to coronavirus disease 2019 infection who received tocilizumab. The secondary objectives were to evaluate ICU-, hospital-, mechanical ventilation-, and vasopressor-free days at da...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajendram, Prabalini, Sacha, Gretchen L., Mehkri, Omar, Wang, Xiaofeng, Han, Xiaozhen, Vachharajani, Vidula, Duggal, Abhijit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808529/
https://www.ncbi.nlm.nih.gov/pubmed/33490955
http://dx.doi.org/10.1097/CCE.0000000000000327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808529/
https://www.ncbi.nlm.nih.gov/pubmed/33490955
http://dx.doi.org/10.1097/CCE.0000000000000327

Ejemplares similares